CareDx agreed to acquire Naveris for up to $260 million in a deal designed to add HPV-driven cancer liquid biopsy testing to its portfolio. The transaction includes $160 million upfront in cash and up to an additional $100 million based on revenue milestones. Naveris contributes NavDx, a tumor-naïve minimal residual disease (MRD) test that measures viral DNA fragments in blood for HPV-associated cancers. CareDx said NavDx received Medicare coverage in 2023 and that it has completed more than 130,000 commercial tests. CareDx CEO John Hanna said the acquisition is targeted and does not signal a broader push into MRD testing beyond the viral-mediated oncology niche, citing embedded specialty workflows and reimbursed monitoring.